These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28122462)

  • 1. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy.
    Selvaraj K; Gowthamarajan K; Karri VV; Barauah UK; Ravisankar V; Jojo GM
    J Drug Target; 2017 Jun; 25(5):386-405. PubMed ID: 28122462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current nanotechnology approaches for the treatment and management of diabetic retinopathy.
    Fangueiro JF; Silva AM; Garcia ML; Souto EB
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):307-22. PubMed ID: 25536109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opening eyes to nanomedicine: Where we are, challenges and expectations on nanotherapy for diabetic retinopathy.
    Campos EJ; Campos A; Martins J; Ambrósio AF
    Nanomedicine; 2017 Aug; 13(6):2101-2113. PubMed ID: 28428052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic and clinical aspects of gene therapy for retinopathy induced by diabetes.
    Ting JH; Martin DK
    Curr Gene Ther; 2006 Apr; 6(2):193-214. PubMed ID: 16611042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
    Wang R; Gao Y; Liu A; Zhai G
    J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence.
    Simó R; Hernández C
    Prog Retin Eye Res; 2015 Sep; 48():160-80. PubMed ID: 25936649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic retinopathy: current management and experimental therapeutic targets.
    Ali TK; El-Remessy AB
    Pharmacotherapy; 2009 Feb; 29(2):182-92. PubMed ID: 19170588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?
    Wang JH; Ling D; Tu L; van Wijngaarden P; Dusting GJ; Liu GS
    Pharmacol Ther; 2017 May; 173():1-18. PubMed ID: 28132907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics.
    Sadasivam R; Packirisamy G; Shakya S; Goswami M
    Nanotheranostics; 2021; 5(2):166-181. PubMed ID: 33564616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology in ocular delivery: current and future directions.
    Sultana Y; Maurya DP; Iqbal Z; Aqil M
    Drugs Today (Barc); 2011 Jun; 47(6):441-55. PubMed ID: 21695286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the understanding and management of diabetic retinopathy.
    Klein R
    Med Clin North Am; 1988 Nov; 72(6):1415-37. PubMed ID: 3054361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of microRNAs in the modulation of diabetic retinopathy.
    Mastropasqua R; Toto L; Cipollone F; Santovito D; Carpineto P; Mastropasqua L
    Prog Retin Eye Res; 2014 Nov; 43():92-107. PubMed ID: 25128741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for diabetic retinopathy.
    Pipis A; Scholl S; Augustin AJ
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):669-81. PubMed ID: 22112046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Concepts in the Treatment of Diabetic Retinopathy.
    Ellis MP; Lent-Schochet D; Lo T; Yiu G
    Curr Diab Rep; 2019 Nov; 19(11):137. PubMed ID: 31748965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic retinopathy: treatment and prevention.
    Dodson PM
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S9-S11. PubMed ID: 17935059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis.
    Silva M; Peng T; Zhao X; Li S; Farhan M; Zheng W
    Adv Drug Deliv Rev; 2021 Jun; 173():439-460. PubMed ID: 33857553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.
    Wang J; Tan J; Luo J; Huang P; Zhou W; Chen L; Long L; Zhang LM; Zhu B; Yang L; Deng DY
    J Nanobiotechnology; 2017 Mar; 15(1):18. PubMed ID: 28249594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing diabetic retinopathy: the partnership between ophthalmologist and primary care physician.
    Chen CJ; Herring J; Chen AS
    J Miss State Med Assoc; 1995 Jul; 36(7):201-8. PubMed ID: 7674296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modern approach to early diagnosis and pathogenetic treatment of diabetic retinopathy].
    Vorob'eva IV
    Vestn Oftalmol; 2016; 132(5):60-67. PubMed ID: 27911427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diabetic eye disease].
    Henriques J; Vaz-Pereira S; Nascimento J; Rosa PC
    Acta Med Port; 2015; 28(1):107-13. PubMed ID: 25817504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.